Market Overview

Mylan And Teva Earnings Are Coming: Here's What To Expect


RBC Capital Markets on Monday issued a note on the specialty pharma space highlighting Mylan NV (NASDAQ: MYL) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) ahead of the companies' earnings announcements on Wednesday and Thursday, respectively. Analyst Randall Stanicky gave his opinion on the two companies.


"We expect a solid EPIPEN driven 4Q and are $0.03 above consensus at $1.30. MYL has been pointing to the upper end of its $4.15 to $4.35 range for 2015 which implies 4Q EPS towards $1.31."

RBC believes that investors should focus on Mylan's message on capital deployment following the attempted hostile takeover of Perrigo Company (NYSE: PRGO) and the likelihood of a transformational deal during 2016, which has the potential to drive top-line growth.


"We expect solid results out of TEVA despite our $1.26 4Q EPS forecast being $0.03 below consensus. However, we do not expect 2016 guidance until 1Q2016 in early May which will follow the closing of the AGN generics deal we expect will come in Mar at this point."

RBC noted that investors should focus on several updates regarding the company's drug pipeline including SD-809 PDUFA in late May. These clinical trials have the potential to drive growth for the company in the near term.

Latest Ratings for MYL

Jul 2019ReiteratesOverweight
Jun 2019Initiates Coverage OnOverweight
May 2019DowngradesOutperformMarket Perform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Randall Stanicky RBC Capital MarketsAnalyst Color Health Care Previews Analyst Ratings Trading Ideas General


Related Articles (MYL + TEVA)

View Comments and Join the Discussion!

Latest Ratings

CHHInitiates Coverage On97.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

KFC Ushers In Third Colonel Sanders In A Year

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts